OBJECTIVE: High plasma adiponectin is associated with reduced risk of type 2 diabetes, probably a consequence of its insulin-sensitizing properties. In vivo data in rodents suggest that the insulin-sensitization responsible for improvement of glycemia occurs in muscle and liver. Whereas associations of plasma adiponectin with muscle insulin sensitivity in humans have been examined, this has not been done for the liver. RESEARCH DESIGN AND METHODS: We therefore analyzed the relationship between fasting plasma adiponectin and basal endogenous glucose production [EGP]-basal) and insulin-suppressed EGP (EGP-insulin, isotope dilution technique) in 143 Pima Indians (94 with normal glucose tolerance, 36 with impaired glucose tolerance, and 16 with type 2 diabetes). RESULTS: Fasting plasma adiponectin concentrations were negatively correlated with EGP-basal and EGP-insulin before (P = 0.006 and P < 0.0001, respectively) as well as after adjustment for age, sex, percent body fat, and insulin-stimulated whole-body glucose uptake (P = 0.007 and P = 0.0005, respectively). CONCLUSIONS: These findings are compatible with the hypothesis that adiponectin increases hepatic insulin sensitivity. Consistent with data in animals, adiponectin may have generalized insulin-sensitizing effects in humans.
OBJECTIVE: High plasma adiponectin is associated with reduced risk of type 2 diabetes, probably a consequence of its insulin-sensitizing properties. In vivo data in rodents suggest that the insulin-sensitization responsible for improvement of glycemia occurs in muscle and liver. Whereas associations of plasma adiponectin with muscle insulin sensitivity in humans have been examined, this has not been done for the liver. RESEARCH DESIGN AND METHODS: We therefore analyzed the relationship between fasting plasma adiponectin and basal endogenous glucose production [EGP]-basal) and insulin-suppressed EGP (EGP-insulin, isotope dilution technique) in 143 Pima Indians (94 with normal glucose tolerance, 36 with impaired glucose tolerance, and 16 with type 2 diabetes). RESULTS: Fasting plasma adiponectin concentrations were negatively correlated with EGP-basal and EGP-insulin before (P = 0.006 and P < 0.0001, respectively) as well as after adjustment for age, sex, percent body fat, and insulin-stimulated whole-body glucose uptake (P = 0.007 and P = 0.0005, respectively). CONCLUSIONS: These findings are compatible with the hypothesis that adiponectinincreases hepatic insulin sensitivity. Consistent with data in animals, adiponectin may have generalized insulin-sensitizing effects in humans.
Authors: P M Catalano; M Hoegh; J Minium; L Huston-Presley; S Bernard; S Kalhan; S Hauguel-De Mouzon Journal: Diabetologia Date: 2006-05-11 Impact factor: 10.122
Authors: J McKee Alderman; Kevin Flurkey; Natasha L Brooks; Sneha B Naik; Jonathan M Gutierrez; Urmila Srinivas; Kristen B Ziara; Linhong Jing; Gunnar Boysen; Rod Bronson; Simon Klebanov; Xian Chen; James A Swenberg; Mats Stridsberg; Carol E Parker; David E Harrison; Terry P Combs Journal: Exp Gerontol Date: 2008-06-07 Impact factor: 4.032
Authors: Marion G Priebe; Renate E Wachters-Hagedoorn; Janneke A J Heimweg; Alexandra Small; Tom Preston; Henk Elzinga; Frans Stellaard; Roel J Vonk Journal: Eur J Nutr Date: 2008-10-13 Impact factor: 5.614
Authors: Jessica A Alvarez; Nikki C Bush; Gary R Hunter; David W Brock; Barbara A Gower Journal: Obesity (Silver Spring) Date: 2008-10-16 Impact factor: 5.002